ennogen pharma ltd Company Information
Company Number
07751819
Website
www.ennogen.comRegistered Address
unit g4, riverside industrial estate, dartford, kent, DA1 5BS
Industry
Wholesale of pharmaceutical goods
Manufacture of basic pharmaceutical products
Telephone
01322629220
Next Accounts Due
September 2024
Group Structure
View All
Directors
Gurdev Ruprai13 Years
Shareholders
gurdev singh ruprai 100%
ennogen pharma ltd Estimated Valuation
Pomanda estimates the enterprise value of ENNOGEN PHARMA LTD at £1.8m based on a Turnover of £1.9m and 0.94x industry multiple (adjusted for size and gross margin).
ennogen pharma ltd Estimated Valuation
Pomanda estimates the enterprise value of ENNOGEN PHARMA LTD at £3.8m based on an EBITDA of £741k and a 5.07x industry multiple (adjusted for size and gross margin).
ennogen pharma ltd Estimated Valuation
Pomanda estimates the enterprise value of ENNOGEN PHARMA LTD at £3.7m based on Net Assets of £1.6m and 2.3x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Ennogen Pharma Ltd Overview
Ennogen Pharma Ltd is a live company located in dartford, DA1 5BS with a Companies House number of 07751819. It operates in the manufacture of basic pharmaceutical products sector, SIC Code 21100. Founded in August 2011, it's largest shareholder is gurdev singh ruprai with a 100% stake. Ennogen Pharma Ltd is a established, small sized company, Pomanda has estimated its turnover at £1.9m with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Ennogen Pharma Ltd Health Check
Pomanda's financial health check has awarded Ennogen Pharma Ltd a 5 rating. We use a traffic light system to show it exceeds the industry average on 5 measures and has 4 areas for improvement. Company Health Check FAQs
![Health Check Image](/assets/images/big_heart.png)
![positive_score](/assets/images/scoreRate2.png)
5 Strong
![positive_score](/assets/images/scoreRate1.png)
2 Regular
![positive_score](/assets/images/scoreRate0.png)
4 Weak
![size](/assets/images/scoreRate0.png)
Size
annual sales of £1.9m, make it smaller than the average company (£28.3m)
- Ennogen Pharma Ltd
£28.3m - Industry AVG
![growth](/assets/images/scoreRate0.png)
Growth
3 year (CAGR) sales growth of -45%, show it is growing at a slower rate (4.1%)
- Ennogen Pharma Ltd
4.1% - Industry AVG
![production](/assets/images/scoreRate1.png)
Production
with a gross margin of 32.4%, this company has a comparable cost of product (32.4%)
- Ennogen Pharma Ltd
32.4% - Industry AVG
![profitability](/assets/images/scoreRate2.png)
Profitability
an operating margin of 39.4% make it more profitable than the average company (5.2%)
- Ennogen Pharma Ltd
5.2% - Industry AVG
![employees](/assets/images/scoreRate0.png)
Employees
with 2 employees, this is below the industry average (87)
2 - Ennogen Pharma Ltd
87 - Industry AVG
![paystructure](/assets/images/scoreRate1.png)
Pay Structure
on an average salary of £65.3k, the company has an equivalent pay structure (£65.3k)
- Ennogen Pharma Ltd
£65.3k - Industry AVG
![efficiency](/assets/images/scoreRate2.png)
Efficiency
resulting in sales per employee of £941k, this is more efficient (£455.9k)
- Ennogen Pharma Ltd
£455.9k - Industry AVG
![debtordays](/assets/images/scoreRate2.png)
Debtor Days
it gets paid by customers after 45 days, this is earlier than average (58 days)
- Ennogen Pharma Ltd
58 days - Industry AVG
![creditordays](/assets/images/scoreRate2.png)
Creditor Days
its suppliers are paid after 175 days, this is slower than average (35 days)
- Ennogen Pharma Ltd
35 days - Industry AVG
![stockdays](/assets/images/scoreRate-1.png)
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Ennogen Pharma Ltd
- - Industry AVG
![cashbalance](/assets/images/scoreRate0.png)
Cash Balance
has cash to cover current liabilities for 7 weeks, this is less cash available to meet short term requirements (12 weeks)
7 weeks - Ennogen Pharma Ltd
12 weeks - Industry AVG
![debtlevel](/assets/images/scoreRate2.png)
Debt Level
it has a ratio of liabilities to total assets of 42%, this is a lower level of debt than the average (51.4%)
42% - Ennogen Pharma Ltd
51.4% - Industry AVG
ENNOGEN PHARMA LTD financials
![ms excel logo](/assets/images/ms_excel_logo.png)
Ennogen Pharma Ltd's latest turnover from December 2022 is estimated at £1.9 million and the company has net assets of £1.6 million. According to their latest financial statements, Ennogen Pharma Ltd has 2 employees and maintains cash reserves of £161.8 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Turnover | |||||||||||
Other Income Or Grants | |||||||||||
Cost Of Sales | |||||||||||
Gross Profit | |||||||||||
Admin Expenses | |||||||||||
Operating Profit | |||||||||||
Interest Payable | |||||||||||
Interest Receivable | |||||||||||
Pre-Tax Profit | |||||||||||
Tax | |||||||||||
Profit After Tax | |||||||||||
Dividends Paid | |||||||||||
Retained Profit | |||||||||||
Employee Costs | |||||||||||
Number Of Employees | 2 | 4 | 7 | 7 | 7 | 9 | 9 | 14 | |||
EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Tangible Assets | 0 | 0 | 198 | 265 | 354 | 472 | 299 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,682,960 | 0 | 0 | 0 |
Total Fixed Assets | 0 | 0 | 198 | 265 | 354 | 472 | 299 | 1,682,960 | 0 | 0 | 0 |
Stock & work in progress | 0 | 650,669 | 1,050,476 | 1,387,246 | 1,117,787 | 959,916 | 507,501 | 373,140 | 379,213 | 600,413 | 57,601 |
Trade Debtors | 232,962 | 399,246 | 106,962 | 3,624,245 | 1,612,444 | 244,841 | 737,176 | 313,383 | 1,750,159 | 201,459 | 91,706 |
Group Debtors | 2,153,212 | 476,466 | 0 | 1,218,658 | 1,218,658 | 1,196,658 | 1,682,960 | 0 | 0 | 0 | 0 |
Misc Debtors | 208,082 | 431,444 | 310,652 | 0 | 0 | 0 | 20,247 | 0 | 0 | 0 | 0 |
Cash | 161,755 | 48,653 | 27,802 | 58,465 | 99,644 | 85,346 | 544,109 | 63,803 | 122,526 | 267,075 | 297,082 |
misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total current assets | 2,756,011 | 2,006,478 | 1,495,892 | 6,288,614 | 4,048,533 | 2,486,761 | 3,491,993 | 750,326 | 2,251,898 | 1,068,947 | 446,389 |
total assets | 2,756,011 | 2,006,478 | 1,496,090 | 6,288,879 | 4,048,887 | 2,487,233 | 3,492,292 | 2,433,286 | 2,251,898 | 1,068,947 | 446,389 |
Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Trade Creditors | 613,141 | 435,381 | 191,539 | 522,674 | 1,903,123 | 260,180 | 59,845 | 70,590 | 2,262,915 | 1,137,671 | 447,173 |
Group/Directors Accounts | 9,474 | 223,982 | 175,527 | 4,822,589 | 717,313 | 0 | 0 | 0 | 0 | 0 | 0 |
other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other current liabilities | 534,930 | 351,856 | 216,926 | 311,293 | 408,326 | 263,747 | 146,897 | 52,868 | 0 | 0 | 0 |
total current liabilities | 1,157,545 | 1,011,219 | 583,992 | 5,656,556 | 3,028,762 | 523,927 | 206,742 | 123,458 | 2,262,915 | 1,137,671 | 447,173 |
loans | 0 | 0 | 0 | 0 | 444,443 | 1,418,157 | 2,917,557 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,270,225 | 0 | 0 | 0 |
provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total long term liabilities | 0 | 0 | 0 | 0 | 444,443 | 1,418,157 | 2,917,557 | 2,270,225 | 0 | 0 | 0 |
total liabilities | 1,157,545 | 1,011,219 | 583,992 | 5,656,556 | 3,473,205 | 1,942,084 | 3,124,299 | 2,393,683 | 2,262,915 | 1,137,671 | 447,173 |
net assets | 1,598,466 | 995,259 | 912,098 | 632,323 | 575,682 | 545,149 | 367,993 | 39,603 | -11,017 | -68,724 | -784 |
total shareholders funds | 1,598,466 | 995,259 | 912,098 | 632,323 | 575,682 | 545,149 | 367,993 | 39,603 | -11,017 | -68,724 | -784 |
Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Operating Activities | |||||||||||
Operating Profit | |||||||||||
Depreciation | 0 | 0 | 67 | 89 | 118 | 158 | 99 | 0 | 0 | 0 | 0 |
Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Tax | |||||||||||
Stock | -650,669 | -399,807 | -336,770 | 269,459 | 157,871 | 452,415 | 134,361 | -6,073 | -221,200 | 542,812 | 57,601 |
Debtors | 1,287,100 | 889,542 | -4,425,289 | 2,011,801 | 1,389,603 | -998,884 | 444,040 | 246,184 | 1,548,700 | 109,753 | 91,706 |
Creditors | 177,760 | 243,842 | -331,135 | -1,380,449 | 1,642,943 | 200,335 | -10,745 | -2,192,325 | 1,125,244 | 690,498 | 447,173 |
Accruals and Deferred Income | 183,074 | 134,930 | -94,367 | -97,033 | 144,579 | 116,850 | 94,029 | 52,868 | 0 | 0 | 0 |
Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash flow from operations | |||||||||||
Investing Activities | |||||||||||
capital expenditure | |||||||||||
Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
cash flow from investments | |||||||||||
Financing Activities | |||||||||||
Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Group/Directors Accounts | -214,508 | 48,455 | -4,647,062 | 4,105,276 | 717,313 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long term loans | 0 | 0 | 0 | -444,443 | -973,714 | -1,499,400 | 2,917,557 | 0 | 0 | 0 | 0 |
Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | -2,270,225 | 2,270,225 | 0 | 0 | 0 |
share issue | |||||||||||
interest | |||||||||||
cash flow from financing | |||||||||||
cash and cash equivalents | |||||||||||
cash | 113,102 | 20,851 | -30,663 | -41,179 | 14,298 | -458,763 | 480,306 | -58,723 | -144,549 | -30,007 | 297,082 |
overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
change in cash | 113,102 | 20,851 | -30,663 | -41,179 | 14,298 | -458,763 | 480,306 | -58,723 | -144,549 | -30,007 | 297,082 |
ennogen pharma ltd Credit Report and Business Information
Ennogen Pharma Ltd Competitor Analysis
![competitor_analysis_table_img](/assets/images/competitor_analysis_table.png)
Perform a competitor analysis for ennogen pharma ltd by selecting its closest rivals, whether from the MANUFACTURING sector, other small companies, companies in DA1 area or any other competitors across 12 key performance metrics.
ennogen pharma ltd Ownership
ENNOGEN PHARMA LTD group structure
Ennogen Pharma Ltd has no subsidiary companies.
Ultimate parent company
ENNOGEN PHARMA LTD
07751819
ennogen pharma ltd directors
Ennogen Pharma Ltd currently has 1 director, Mr Gurdev Ruprai serving since Aug 2011.
officer | country | age | start | end | role |
---|---|---|---|---|---|
Mr Gurdev Ruprai | 64 years | Aug 2011 | - | Director |
P&L
December 2022turnover
1.9m
-21%
operating profit
741k
0%
gross margin
32.4%
-3.11%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2022net assets
1.6m
+0.61%
total assets
2.8m
+0.37%
cash
161.8k
+2.32%
net assets
Total assets minus all liabilities
ennogen pharma ltd company details
company number
07751819
Type
Private limited with Share Capital
industry
46460 - Wholesale of pharmaceutical goods
21100 - Manufacture of basic pharmaceutical products
incorporation date
August 2011
age
13
accounts
Small Company
ultimate parent company
previous names
N/A
incorporated
UK
address
unit g4, riverside industrial estate, dartford, kent, DA1 5BS
last accounts submitted
December 2022
ennogen pharma ltd Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 2 charges/mortgages relating to ennogen pharma ltd. Currently there are 1 open charges and 1 have been satisfied in the past.
![charges](/assets/images/company_charges.png)
ennogen pharma ltd Companies House Filings - See Documents
date | description | view/download |
---|